Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers

NCT02140996 is registered in ClinicalTrials.gov with Singapore Clinical Research Institute as lead sponsor.

NCT NCT02140996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02140996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers
Lead sponsor
Singapore Clinical Research Institute
Phase
Phase 1
Overall status
Unknown status
Start date
September 30, 2014
Completion date
June 30, 2017
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial cancers of the lung, breast, ovary, prostate and colon